42
Participants
Start Date
March 31, 2012
Primary Completion Date
October 31, 2014
Study Completion Date
March 31, 2016
pazopanib
Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
Pennsylvania Oncology Hematology Associates, Philadelphia
Washington Cancer Institute, Washington D.C.
West Clinic, Memphis
University of Iowa, Iowa City
University of Minnesota, Minneapolis
Oncology Specialists, SC, Niles
MD Anderson Cancer Center, Houston
Kootenai Cancer Center, Post Falls
Sarcoma Oncology Center, Santa Monica
Lead Sponsor
Collaborators (1)
Novartis
INDUSTRY
Vector Oncology
OTHER